The Role of the Clinical Pharmacist in the Identification and Management of Corticophobia – An Interventional Study

Objective: To study the effects of medication reconciliation and patient counseling on the overall health benefits of the patients in the department of gastroenterology. Methods: This study is a prospective interventional study, was conducted in a 500 bedded MNR Hospital. The sample size taken was 150 patients and the study population comprised of patients aged 18-80 y, admitted in the hospital during the study period of six months. Results: Out of 150 patients, there were 98 (65.33%) male patients and 52 (34.67%) female patients. Patients between 18 and 30 y of age were 29(19.33%), between the age of 30 and 50 y were 71 (47.33%) and above 50 were 50(33.33%). Pancreatitis was most prevalent with 21% of total prevalence, followed by CLD and cholelithiasis with 17%, then IBD 16%, PUD and Gastritis 5%, GERD 4% and other diseases 15%. Conclusion: The basic role of the pharmacist, is to help in minimizing the errors and to perform medication reconciliation. In patient counseling, pharmacists provide information about the disease, and the medications to increase patient safety and the changes in the behavior for the better outcome.

Download Full-text

A PILOT STUDY ON IDENTIFICATION AND MANAGEMENT OF DRUG INDUCED SEXUAL DYSFUNCTION: A COLLABORATIVE APPROACH BY CLINICAL PHARMACIST AND PSYCHIATRIST

International Journal of Pharmacy and Pharmaceutical Sciences ◽

10.22159/ijpps.2020v12i2.34334 ◽

2019 ◽

pp. 32-37 ◽

Cited By ~ 1

Author(s):

BILESH SHAKYA ◽

TIRIN BABU ◽

MOHAMED SHAFI P. ◽

VEMURI TEJASRI ◽

JUNY SEBASTIAN ◽

...

Keyword(s):

Sexual Dysfunction ◽

Clinical Pharmacist ◽

Sexual Experience ◽

University Hospital ◽

Interventional Study ◽

Drug Induced ◽

Medical Practitioners ◽

Vaginal Lubrication ◽

Psychiatric Department

Objective: To assess the role of clinical pharmacists in the identification and management of drug-induced sexual dysfunction in collaboration with the psychiatrist and also to determine the prevalence and pattern of drug-induced sexual dysfunction, identify nature and extend of drug-induced sexual dysfunction, and assess the pattern of management of drug-induced sexual dysfunction. Methods: This periodic prevalence interventional study was carried out among patients who visited the psychiatric department of a university hospital over three month’s period. Patients were screened for sexual dysfunction using the Arizona Sexual Experience Scale (ASEX) by study pharmacists. Results: Of the 100 patients reviewed, only 50% of subjects met the study criteria. Depression (42%) was the most common clinical diagnosis among the study patients. The overall prevalence of drug-induced sexual dysfunction was 16%. A higher incidence of drug-induced sexual dysfunction was observed in men (62.5%). Decrease libido (40%) was the most prominently observed drug-induced sexual dysfunction in both genders. Antidepressant (50%) was the most common class of drugs implicated in sexual dysfunction. Drug-induced sexual dysfunction was pharmacologically managed with vaginal lubrication (40%), Tadalafil (20%) and Tadalafil+Dapoxetine combination (40%). Conclusion: With this study, provided a vision, further how prospective studies in this arena may be carried out for better understanding drug-induced sexual dysfunction and how a clinical pharmacist can contribute for better health care of patients in the sex clinic by collaborating with medical practitioners.

Download Full-text

Role of clinical pharmacist in the medication adherence behaviour of cancer patients: An interventional study

Le Pharmacien Hospitalier et Clinicien ◽

10.1016/j.phclin.2021.05.002 ◽

2021 ◽

Author(s):

Anisty Maria Joy ◽

Nandakumar UP ◽

Sharad Chand ◽

Jayaram Shetty K ◽

Sophia M. George ◽

...

Keyword(s):

Medication Adherence ◽

Cancer Patients ◽

Clinical Pharmacist ◽

Interventional Study ◽

Adherence Behaviour

Download Full-text

The role of the clinical pharmacist in guiding adjuvant hormonal therapy in patients with breast cancer

Journal of Oncology Pharmacy Practice ◽

10.1177/10781552211029361 ◽

2021 ◽

pp. 107815522110293

Author(s):

Amanda V Pirolli ◽

Tatiana Brusamarello ◽

Stella S Everton ◽

Vânia M S Andrzejevski

Keyword(s):

Breast Cancer ◽

Hormone Therapy ◽

Hormonal Therapy ◽

Clinical Pharmacist ◽

Tertiary Care ◽

Structured Interview ◽

Care Hospital ◽

Adjuvant Hormonal Therapy ◽

Breast Cancers

Breast cancer is the most prevalent type of cancer among women, affecting about 2.1 million worldwide and is responsible for the highest number of cancer-related deaths among women. Approximately 80% of breast cancers express on the surface of hormone receptor cells, such as progesterone and estrogen. In these cases, Adjuvant Hormonal Therapy (AHT) is indicated for a period of five to ten years and consists of taking a daily oral pill. The two most used drugs in AHT are tamoxifen and Aromatase Inhibitors. One of the issues most faced by individuals who are subjected to long periods of treatment is the lack of medication adherence and, consequently, therapeutic inefficiency. It is believed that the monitoring by the pharmacist can contribute to the reduction of errors inherent to the medication, making the treatment more effective and improving the patient's quality of life. The present study aimed to know the perception of patients who live with breast cancer and who do AHT in relation to the educational performance of the clinical pharmacist. This is a qualitative, descriptive and exploratory study, carried out from March to October 2020, with 15 women undergoing treatment at the oncology unit of a tertiary-care hospital in south of Brazil. The data were obtained through a semi-structured interview using an instrument composed of two parts, one referring to the characterization of the participants and the other with the guiding question of the research: "How do you perceive the role of the pharmacist in relation to the guidelines for the use of adjuvant hormonal therapy?". The method of theoretical saturation was used to perform the sample closure and the thematic analysis was used to analyze the data. The participants were between 32 and 74 years old, seven were on tamoxifen therapy and eight on anastrozole, ten were on the first year of treatment, two on the second and three on the third year. The themes that emerged were: pharmacist-patient interaction as a safety factor in hormone therapy; role of the pharmacist in the development of strategies for self-management of the patients during hormone therapy; and, challenges for the pharmacist in relation to hormone therapy through continued guidance. It was evident that the pharmacist's educational action encouraged the participants to carry out the treatment in a more confident and assertive manner according to their particularities and beliefs.

Download Full-text

The Effectiveness of Glutathione Redox Status as a Possible Tumor Marker in Colorectal Cancer

International Journal of Molecular Sciences ◽

10.3390/ijms22126183 ◽

2021 ◽

Vol 22 (12) ◽

pp. 6183

Author(s):

Delia Acevedo-León ◽

Lidia Monzó-Beltrán ◽

Segundo Ángel Gómez-Abril ◽

Nuria Estañ-Capell ◽

Natalia Camarasa-Lillo ◽

...

Keyword(s):

Colorectal Cancer ◽

Redox State ◽

Reduced Glutathione ◽

Redox Status ◽

Oxidation Products ◽

Interventional Study ◽

Thiol Redox State ◽

Thiol Redox ◽

Glutathione Redox

The role of oxidative stress (OS) in cancer is a matter of great interest due to the implication of reactive oxygen species (ROS) and their oxidation products in the initiation of tumorigenesis, its progression, and metastatic dissemination. Great efforts have been made to identify the mechanisms of ROS-induced carcinogenesis; however, the validation of OS byproducts as potential tumor markers (TMs) remains to be established. This interventional study included a total of 80 colorectal cancer (CRC) patients and 60 controls. By measuring reduced glutathione (GSH), its oxidized form (GSSG), and the glutathione redox state in terms of the GSSG/GSH ratio in the serum of CRC patients, we identified significant changes as compared to healthy subjects. These findings are compatible with the effectiveness of glutathione as a TM. The thiol redox state showed a significant increase towards oxidation in the CRC group and correlated significantly with both the tumor state and the clinical evolution. The sensitivity and specificity of serum glutathione levels are far above those of the classical TMs CEA and CA19.9. We conclude that the GSSG/GSH ratio is a simple assay which could be validated as a novel clinical TM for the diagnosis and monitoring of CRC.

Download Full-text